leadf
logo-loader
TSX:CRDL OTCQX:CRTPF

Cardiol Therapeutics

Receive alerts
Market:
TSX
Market Cap:
$128.62 m
Price
3.92 CAD
Change
-3.45%
52 weeks high
5.32
52 weeks low
1.87

In brief

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a clinical-stage biotechnology company focused on developing therapies for inflammatory heart disease. The Company has received approval from the U.S. FDA for its Investigational New Drug application to commence a Phase II/III clinical trial to investigate its lead product, CardiolRx™, in hospitalized COVID-19 patients with a history of, or risk factors for, cardiovascular disease. CardiolRx™ is a pharmaceutically produced, cGMP certified, THC free (<10 ppm) oral cannabidiol formulation. Cardiol is also planning a Phase 2 trial in acute myocarditis. The Company recently launched Cortalex™, www.cortalex.com, the first THC-free extra-strength formulation of cannabidiol oil available across Canada online at Medical Cannabis by Shoppers.

Snapshot

The group's flagship product, CardiolRx, is formulated to be one of the safest and most consistent CBD medicines available on the market

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Cardiol CEO sees bright future for pharmaceutically produced cannabidiol after blockbuster Jazz-GW Pharmaceutical deal

Market watchers say the deal may lend further legitimacy to a growing segment of cannabis companies that focus on pharmaceutically produced products

1 month ago